On 10th February 2021, the Hypo-RESOLVE Managing Board convened virtually to discuss progress achieved over the past couple of months. Notable achievements, amongst others, were the start of recruitment for the clinical study, which for the time being is mostly conducted virtually and is rapidly gaining momentum, as well as the positive response on the EMA Qualification Advice which the consortium sought regarding its PRO development and received from the EMA. The next Managing Board meeting has been scheduled for May 2021.